<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;ff=20240925021515&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;ff=20240925021515&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 25 Sep 2024 06:15:16 +0000</lastbuilddate>
<pubDate>Tue, 24 Sep 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Turning back time: the promise of cardiac regeneration</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39317841/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240925021515&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Sep 24. doi: 10.1038/s41569-024-01085-z. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39317841/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240925021515&v=2.18.0.post9+e462414">39317841</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01085-z>10.1038/s41569-024-01085-z</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39317841</guid>
<pubDate>Tue, 24 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Elsa Lawrence</dc:creator>
<dc:creator>Catherine H Wilson</dc:creator>
<dc:date>2024-09-24</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Turning back time: the promise of cardiac regeneration</dc:title>
<dc:identifier>pmid:39317841</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01085-z</dc:identifier>
</item>
<item>
<title>Minority stress, discrimination and cardiovascular health</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39317840/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240925021515&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Sep 24. doi: 10.1038/s41569-024-01083-1. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39317840/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240925021515&v=2.18.0.post9+e462414">39317840</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01083-1>10.1038/s41569-024-01083-1</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39317840</guid>
<pubDate>Tue, 24 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>John C Lin</dc:creator>
<dc:creator>Dang Nguyen</dc:creator>
<dc:creator>Anthony Zhong</dc:creator>
<dc:date>2024-09-24</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Minority stress, discrimination and cardiovascular health</dc:title>
<dc:identifier>pmid:39317840</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01083-1</dc:identifier>
</item>
<item>
<title>20 years of Nature Reviews Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39317839/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240925021515&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Sep 24. doi: 10.1038/s41569-024-01090-2. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39317839/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240925021515&v=2.18.0.post9+e462414">39317839</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01090-2>10.1038/s41569-024-01090-2</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39317839</guid>
<pubDate>Tue, 24 Sep 2024 06:00:00 -0400</pubDate>
<dc:date>2024-09-24</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>20 years of Nature Reviews Cardiology</dc:title>
<dc:identifier>pmid:39317839</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01090-2</dc:identifier>
</item>
<item>
<title>Soil and water pollution and cardiovascular disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39317838/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240925021515&amp;v=2.18.0.post9+e462414
      <description>Healthy, uncontaminated soils and clean water support all life on Earth and are essential for human health. Chemical pollution of soil, water, air and food is a major environmental threat, leading to an estimated 9 million premature deaths worldwide. The Global Burden of Disease study estimated that pollution was responsible for 5.5 million deaths related to cardiovascular disease (CVD) in 2019. Robust evidence has linked multiple pollutants, including heavy metals, pesticides, dioxins and toxic...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Sep 25. doi: 10.1038/s41569-024-01068-0. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Healthy, uncontaminated soils and clean water support all life on Earth and are essential for human health. Chemical pollution of soil, water, air and food is a major environmental threat, leading to an estimated 9 million premature deaths worldwide. The Global Burden of Disease study estimated that pollution was responsible for 5.5 million deaths related to cardiovascular disease (CVD) in 2019. Robust evidence has linked multiple pollutants, including heavy metals, pesticides, dioxins and toxic synthetic chemicals, with increased risk of CVD, and some reports suggest an association between microplastic and nanoplastic particles and CVD. Pollutants in soil diminish its capacity to produce food, leading to crop impurities, malnutrition and disease, and they can seep into rivers, worsening water pollution. Deforestation, wildfires and climate change exacerbate pollution by triggering soil erosion and releasing sequestered pollutants into the air and water. Despite their varied chemical makeup, pollutants induce CVD through common pathophysiological mechanisms involving oxidative stress and inflammation. In this Review, we provide an overview of the relationship between soil and water pollution and human health and pathology, and discuss the prevalence of soil and water pollutants and how they contribute to adverse health effects, focusing on CVD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39317838/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240925021515&v=2.18.0.post9+e462414">39317838</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01068-0>10.1038/s41569-024-01068-0</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39317838</guid>
<pubDate>Tue, 24 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Thomas Münzel</dc:creator>
<dc:creator>Omar Hahad</dc:creator>
<dc:creator>Jos Lelieveld</dc:creator>
<dc:creator>Michael Aschner</dc:creator>
<dc:creator>Mark J Nieuwenhuijsen</dc:creator>
<dc:creator>Philip J Landrigan</dc:creator>
<dc:creator>Andreas Daiber</dc:creator>
<dc:date>2024-09-24</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Soil and water pollution and cardiovascular disease</dc:title>
<dc:identifier>pmid:39317838</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01068-0</dc:identifier>
</item>
<item>
<title>Light-induced remodeling of phytochrome B enables signal transduction by phytochrome-interacting factor</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39317197/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240925021515&amp;v=2.18.0.post9+e462414
      <description>Phytochrome B (phyB) and phytochrome-interacting factors (PIFs) constitute a well-established signaling module critical for plants adapting to ambient light. However, mechanisms underlying phyB photoactivation and PIF binding for signal transduction remain elusive. Here, we report the cryo-electron microscopy (cryo-EM) structures of the photoactivated phyB or the constitutively active phyB^(Y276H) mutant in complex with PIF6, revealing a similar trimer. The light-induced configuration switch of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 16:S0092-8674(24)01023-7. doi: 10.1016/j.cell.2024.09.005. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Phytochrome B (phyB) and phytochrome-interacting factors (PIFs) constitute a well-established signaling module critical for plants adapting to ambient light. However, mechanisms underlying phyB photoactivation and PIF binding for signal transduction remain elusive. Here, we report the cryo-electron microscopy (cryo-EM) structures of the photoactivated phyB or the constitutively active phyB<sup>Y276H</sup> mutant in complex with PIF6, revealing a similar trimer. The light-induced configuration switch of the chromophore drives a conformational transition of the nearby tongue signature within the phytochrome-specific (PHY) domain of phyB. The resulting α-helical PHY tongue further disrupts the head-to-tail dimer of phyB in the dark-adapted state. These structural remodelings of phyB facilitate the induced-fit recognition of PIF6, consequently stabilizing the N-terminal extension domain and a head-to-head dimer of activated phyB. Interestingly, the phyB dimer exhibits slight asymmetry, resulting in the binding of only one PIF6 molecule. Overall, our findings solve a key question with respect to how light-induced remodeling of phyB enables PIF signaling in phytochrome research.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39317197/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240925021515&v=2.18.0.post9+e462414">39317197</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.005>10.1016/j.cell.2024.09.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39317197</guid>
<pubDate>Tue, 24 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Zhengdong Wang</dc:creator>
<dc:creator>Wenfeng Wang</dc:creator>
<dc:creator>Didi Zhao</dc:creator>
<dc:creator>Yanping Song</dc:creator>
<dc:creator>Xiaoli Lin</dc:creator>
<dc:creator>Meng Shen</dc:creator>
<dc:creator>Cheng Chi</dc:creator>
<dc:creator>Bin Xu</dc:creator>
<dc:creator>Jun Zhao</dc:creator>
<dc:creator>Xing Wang Deng</dc:creator>
<dc:creator>Jizong Wang</dc:creator>
<dc:date>2024-09-24</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Light-induced remodeling of phytochrome B enables signal transduction by phytochrome-interacting factor</dc:title>
<dc:identifier>pmid:39317197</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.005</dc:identifier>
</item>
<item>
<title>2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39316661/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240925021515&amp;v=2.18.0.post9+e462414
      <description>AIM: The "2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery" provides recommendations to guide clinicians in the perioperative cardiovascular evaluation and management of adult patients undergoing noncardiac surgery.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 24. doi: 10.1161/CIR.0000000000001285. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">AIM: The "2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery" provides recommendations to guide clinicians in the perioperative cardiovascular evaluation and management of adult patients undergoing noncardiac surgery.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A comprehensive literature search was conducted from August 2022 to March 2023 to identify clinical studies, reviews, and other evidence conducted on human subjects that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">STRUCTURE: Recommendations from the "2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery" have been updated with new evidence consolidated to guide clinicians; clinicians should be advised this guideline supersedes the previously published 2014 guideline. In addition, evidence-based management strategies, including pharmacological therapies, perioperative monitoring, and devices, for cardiovascular disease and associated medical conditions, have been developed.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39316661/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240925021515&v=2.18.0.post9+e462414">39316661</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001285>10.1161/CIR.0000000000001285</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39316661</guid>
<pubDate>Tue, 24 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Annemarie Thompson</dc:creator>
<dc:creator>Kirsten E Fleischmann</dc:creator>
<dc:creator>Nathaniel R Smilowitz</dc:creator>
<dc:creator>Lisa de Las Fuentes</dc:creator>
<dc:creator>Debabrata Mukherjee</dc:creator>
<dc:creator>Niti R Aggarwal</dc:creator>
<dc:creator>Faraz S Ahmad</dc:creator>
<dc:creator>Robert B Allen</dc:creator>
<dc:creator>S Elissa Altin</dc:creator>
<dc:creator>Andrew Auerbach</dc:creator>
<dc:creator>Jeffrey S Berger</dc:creator>
<dc:creator>Benjamin Chow</dc:creator>
<dc:creator>Habib A Dakik</dc:creator>
<dc:creator>Eric L Eisenstein</dc:creator>
<dc:creator>Marie Gerhard-Herman</dc:creator>
<dc:creator>Kamrouz Ghadimi</dc:creator>
<dc:creator>Bessie Kachulis</dc:creator>
<dc:creator>Jacinthe Leclerc</dc:creator>
<dc:creator>Christopher S Lee</dc:creator>
<dc:creator>Tracy E Macaulay</dc:creator>
<dc:creator>Gail Mates</dc:creator>
<dc:creator>Geno J Merli</dc:creator>
<dc:creator>Purvi Parwani</dc:creator>
<dc:creator>Jeanne E Poole</dc:creator>
<dc:creator>Michael W Rich</dc:creator>
<dc:creator>Kurt Ruetzler</dc:creator>
<dc:creator>Steven C Stain</dc:creator>
<dc:creator>BobbieJean Sweitzer</dc:creator>
<dc:creator>Amy W Talbot</dc:creator>
<dc:creator>Saraschandra Vallabhajosyula</dc:creator>
<dc:creator>John Whittle</dc:creator>
<dc:creator>Kim Allan Williams</dc:creator>
<dc:date>2024-09-24</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</dc:title>
<dc:identifier>pmid:39316661</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001285</dc:identifier>
</item>
<item>
<title>Sex-specific differences in alive hospital discharge following infrarenal abdominal aortic aneurysm repair</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39315612/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240925021515&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Women have a 25% lower rate of alive discharge after aortic surgery, despite adjustment for pre/peri- and postoperative parameters. Efforts to increase rate of alive hospital discharge for women should be sought.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 24:ehae675. doi: 10.1093/eurheartj/ehae675. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: A longer time to alive hospital discharge following infrarenal abdominal aortic aneurysm (AAA) repair is associated with reduced patient-satisfaction and increased length of stay, hospital-acquired deconditioning, infection and costs. This study investigated sex-specific differences in, and drivers of, the rate of alive hospital discharge.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Examination of UK National Vascular Registry (UK NVR), 2014-2019 and Swedish National Patient Registry (SE NPR) elective AAA patients, 2010-2018, for endovascular (EVAR) or open (OAR) aneurysm repair. Cox models assessed sex-specific difference in rate of alive hospital discharge, adjusting for co-morbidity, anatomy, standard-of-care, post-operative complications, and year, with in-hospital death as the competing risk.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: 29,751 AAA repairs (UK NVR -EVAR 12518:1532; OAR 6803:837; SE NPR - EVAR 4234:792; OAR 2638:497, men:women) were assessed. For EVAR, the unadjusted rate of alive hospital discharge was ∼25% lower for women (UK NVR HR 0.75 [0.71-0.80], p&lt;.001; SE NPR HR 0.75 [0.69-0.81], p&lt;.001). Following adjustment the sex-specific hazard ratio narrowed but remained significant (UK NVR: HR 0.83 [0.79-0.88], p&lt;.001; SE NPR HR 0.83 [0.76-0.89], p&lt;.001). For OAR, the rate of alive hospital discharge was 23-27% lower for women (UK NVR HR 0.73 [0.67-0.78], p&lt;.001; SE NPR HR 0.77 [0.70-0.85], p&lt;.001). Following adjustment the sex-specific hazard ratio narrowed (UK NVR HR 0.82 [0.76-0.88], p&lt;.001; SE NPR HR 0.79 [0.72-0.88], p&lt;.001) but remained significant.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Women have a 25% lower rate of alive discharge after aortic surgery, despite adjustment for pre/peri- and postoperative parameters. Efforts to increase rate of alive hospital discharge for women should be sought.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39315612/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240925021515&v=2.18.0.post9+e462414">39315612</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae675>10.1093/eurheartj/ehae675</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39315612</guid>
<pubDate>Tue, 24 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Anna Louise Pouncey</dc:creator>
<dc:creator>Michael J Sweeting</dc:creator>
<dc:creator>Colin Bicknell</dc:creator>
<dc:creator>Janet T Powell</dc:creator>
<dc:creator>Jenny Lübcke</dc:creator>
<dc:creator>Kim Gunnarsson</dc:creator>
<dc:creator>Anders Wanhainen</dc:creator>
<dc:creator>Kevin Mani</dc:creator>
<dc:date>2024-09-24</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Sex-specific differences in alive hospital discharge following infrarenal abdominal aortic aneurysm repair</dc:title>
<dc:identifier>pmid:39315612</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae675</dc:identifier>
</item>
<item>
<title>Circulating Autoantibodies Targeting TREK-1 in Patients With Short-Coupled Ventricular Fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39315453/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240925021515&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Patients with SCVF harbor circulating autoantibodies against the cardiac TREK-1 channel. Anti-TREK-1 autoantibodies not only present the first reported biomarker for SCVF, but our functional studies also suggest a direct implication in the arrhythmogenesis of SCVF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 24. doi: 10.1161/CIRCULATIONAHA.124.070284. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Short-coupled ventricular fibrillation (SCVF) is increasingly being recognized as a distinct primary electrical disorder and cause of otherwise unexplained cardiac arrest. However, the pathophysiology of SCVF remains largely elusive. Despite extensive genetic screening, there is no convincing evidence of a robust monogenic disease gene, thus raising the speculations for alternative pathogeneses. The role of autoimmune mechanisms in SCVF has not been investigated so far. The objective of this study was to screen for circulating autoantibodies in patients with SCVF and assess their role in arrhythmogenesis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This is a prospective, single-center, case-control study enrolling cardiac arrest survivors diagnosed with SCVF or idiopathic ventricular fibrillation (IVF) between 2019 and 2023 at the Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval Inherited Arrhythmia Clinic in Canada. Plasma samples were screened for autoantibodies targeting cardiac ion channels using peptide microarray technology. Identified target autoantibodies were then purified from pooled plasma samples for subsequent cellular electrophysiological studies.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Fourteen patients with SCVF (n=4 [29%] female patients; median age, 45 years [36, 58]; n=14 [100%] non-Hispanic White) and 19 patients with idiopathic ventricular fibrillation (n=8 [42%] female patients; median age, 49 years [38, 57]; n=19 [100%] non-Hispanic White) were enrolled in the study and compared with 38 (n=20 [53%] female subjects; median age, 45 years [29, 66]; n=36 [95%] non-Hispanic White) sex-, age- and ethnicity-matched healthy controls. During the study period, 11 (79%) SCVF probands experienced ventricular fibrillation recurrence after a median of 4.3 months (interquartile range, 0.3-20.7). Autoantibodies targeting cardiac TREK-1 (TWIK [tandem of pore-domains in a weakly inward rectifying potassium channel]-related potassium channel 1 were identified in 7 (50%) patients with SCVF (<i>P</i>=0.049). Patch clamp experiments demonstrated channel-activating properties of anti-TREK-1 autoantibodies that are antagonized by quinidine in both HEK293 cells and human induced pluripotent stem cell-derived cardiomyocytes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Patients with SCVF harbor circulating autoantibodies against the cardiac TREK-1 channel. Anti-TREK-1 autoantibodies not only present the first reported biomarker for SCVF, but our functional studies also suggest a direct implication in the arrhythmogenesis of SCVF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39315453/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240925021515&v=2.18.0.post9+e462414">39315453</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070284>10.1161/CIRCULATIONAHA.124.070284</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39315453</guid>
<pubDate>Tue, 24 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Jin Li</dc:creator>
<dc:creator>Alexandre Janin</dc:creator>
<dc:creator>Mona Patoughi</dc:creator>
<dc:creator>Nathalie Gaudreault</dc:creator>
<dc:creator>Lenke Kis</dc:creator>
<dc:creator>Hamid Moha Ou Maat</dc:creator>
<dc:creator>Yohan Bossé</dc:creator>
<dc:creator>Christian Steinberg</dc:creator>
<dc:date>2024-09-24</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Circulating Autoantibodies Targeting TREK-1 in Patients With Short-Coupled Ventricular Fibrillation</dc:title>
<dc:identifier>pmid:39315453</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070284</dc:identifier>
</item>
<item>
<title>Core Components of Cardiac Rehabilitation Programs: 2024 Update: A Scientific Statement From the American Heart Association and the American Association of Cardiovascular and Pulmonary Rehabilitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39315436/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240925021515&amp;v=2.18.0.post9+e462414
      <description>The science of cardiac rehabilitation and the secondary prevention of cardiovascular disease has progressed substantially since the most recent American Heart Association and American Association of Cardiovascular and Pulmonary Rehabilitation update on the core components of cardiac rehabilitation and secondary prevention programs was published in 2007. In addition, the advent of new care models, including virtual and remote delivery of cardiac rehabilitation services, has expanded the ways that...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 24. doi: 10.1161/CIR.0000000000001289. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The science of cardiac rehabilitation and the secondary prevention of cardiovascular disease has progressed substantially since the most recent American Heart Association and American Association of Cardiovascular and Pulmonary Rehabilitation update on the core components of cardiac rehabilitation and secondary prevention programs was published in 2007. In addition, the advent of new care models, including virtual and remote delivery of cardiac rehabilitation services, has expanded the ways that cardiac rehabilitation programs can reach patients. In this scientific statement, we update the scientific basis of the core components of patient assessment, nutritional counseling, weight management and body composition, cardiovascular disease and risk factor management, psychosocial management, aerobic exercise training, strength training, and physical activity counseling. In addition, in recognition that high-quality cardiac rehabilitation programs regularly monitor their processes and outcomes and engage in an ongoing process of quality improvement, we introduce a new core component of program quality. High-quality program performance will be essential to improve widely documented low enrollment and adherence rates and reduce health disparities in cardiac rehabilitation access.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39315436/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240925021515&v=2.18.0.post9+e462414">39315436</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001289>10.1161/CIR.0000000000001289</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39315436</guid>
<pubDate>Tue, 24 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Todd M Brown</dc:creator>
<dc:creator>Quinn R Pack</dc:creator>
<dc:creator>Ellen Aberegg</dc:creator>
<dc:creator>LaPrincess C Brewer</dc:creator>
<dc:creator>Yvonne R Ford</dc:creator>
<dc:creator>Daniel E Forman</dc:creator>
<dc:creator>Emily C Gathright</dc:creator>
<dc:creator>Sherrie Khadanga</dc:creator>
<dc:creator>Cemal Ozemek</dc:creator>
<dc:creator>Randal J Thomas</dc:creator>
<dc:creator>American Heart Association Exercise, Cardiac Rehabilitation and Secondary Prevention Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Lifestyle and Cardiometabolic Health; and Council on Quality of Care and Outcomes Research</dc:creator>
<dc:date>2024-09-24</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Core Components of Cardiac Rehabilitation Programs: 2024 Update: A Scientific Statement From the American Heart Association and the American Association of Cardiovascular and Pulmonary Rehabilitation</dc:title>
<dc:identifier>pmid:39315436</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001289</dc:identifier>
</item>
<item>
<title>Assays of Variant Effect and Automated Patch Clamping Improve &lt;em>;KCNH2&lt;/em>;-LQTS Variant Classification and Cardiac Event Risk Stratification</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39315434/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240925021515&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: High-throughput KCNH2 variant MAVE data meaningfully contribute to variant classification at scale, whereas long QT syndrome penetrance estimates and automated patch clamping peak tail current measurements meaningfully contribute to risk stratification of cardiac events in patients with heterozygous KCNH2 missense variants.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 24. doi: 10.1161/CIRCULATIONAHA.124.069828. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Long QT syndrome is a lethal arrhythmia syndrome, frequently caused by rare loss-of-function variants in the potassium channel encoded by <i>KCNH2</i>. Variant classification is difficult, often because of lack of functional data. Moreover, variant-based risk stratification is also complicated by heterogenous clinical data and incomplete penetrance. Here we sought to test whether variant-specific information, primarily from high-throughput functional assays, could improve both classification and cardiac event risk stratification in a large, harmonized cohort of <i>KCNH2</i> missense variant heterozygotes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We quantified cell-surface trafficking of 18 796 variants in <i>KCNH2</i> using a multiplexed assay of variant effect (MAVE). We recorded KCNH2 current density for 533 variants by automated patch clamping. We calibrated the strength of evidence of MAVE data according to ClinGen guidelines. We deeply phenotyped 1458 patients with <i>KCNH2</i> missense variants, including QTc, cardiac event history, and mortality. We correlated variant functional data and Bayesian long QT syndrome penetrance estimates with cohort phenotypes and assessed hazard ratios for cardiac events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Variant MAVE trafficking scores and automated patch clamping peak tail currents were highly correlated (Spearman rank-order ρ=0.69; n=433). The MAVE data were found to provide up to pathogenic very strong evidence for severe loss-of-function variants. In the cohort, both functional assays and Bayesian long QT syndrome penetrance estimates were significantly predictive of cardiac events when independently modeled with patient sex and adjusted QT interval (QTc); however, MAVE data became nonsignificant when peak tail current and penetrance estimates were also available. The area under the receiver operator characteristic curve for 20-year event outcomes based on patient-specific sex and QTc (area under the curve, 0.80 [0.76-0.83]) was improved with prospectively available penetrance scores conditioned on MAVE (area under the curve, 0.86 [0.83-0.89]) or attainable automated patch clamping peak tail current data (area under the curve, 0.84 [0.81-0.88]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: High-throughput <i>KCNH2</i> variant MAVE data meaningfully contribute to variant classification at scale, whereas long QT syndrome penetrance estimates and automated patch clamping peak tail current measurements meaningfully contribute to risk stratification of cardiac events in patients with heterozygous <i>KCNH2</i> missense variants.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39315434/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240925021515&v=2.18.0.post9+e462414">39315434</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069828>10.1161/CIRCULATIONAHA.124.069828</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39315434</guid>
<pubDate>Tue, 24 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Matthew J O'Neill</dc:creator>
<dc:creator>Chai-Ann Ng</dc:creator>
<dc:creator>Takanori Aizawa</dc:creator>
<dc:creator>Luca Sala</dc:creator>
<dc:creator>Sahej Bains</dc:creator>
<dc:creator>Annika Winbo</dc:creator>
<dc:creator>Rizwan Ullah</dc:creator>
<dc:creator>Qianyi Shen</dc:creator>
<dc:creator>Chek-Ying Tan</dc:creator>
<dc:creator>Krystian Kozek</dc:creator>
<dc:creator>Loren R Vanags</dc:creator>
<dc:creator>Devyn W Mitchell</dc:creator>
<dc:creator>Alex Shen</dc:creator>
<dc:creator>Yuko Wada</dc:creator>
<dc:creator>Asami Kashiwa</dc:creator>
<dc:creator>Lia Crotti</dc:creator>
<dc:creator>Federica Dagradi</dc:creator>
<dc:creator>Giulia Musu</dc:creator>
<dc:creator>Carla Spazzolini</dc:creator>
<dc:creator>Raquel Neves</dc:creator>
<dc:creator>J Martijn Bos</dc:creator>
<dc:creator>John R Giudicessi</dc:creator>
<dc:creator>Xavier Bledsoe</dc:creator>
<dc:creator>Eric R Gamazon</dc:creator>
<dc:creator>Megan C Lancaster</dc:creator>
<dc:creator>Andrew M Glazer</dc:creator>
<dc:creator>Bjorn C Knollmann</dc:creator>
<dc:creator>Dan M Roden</dc:creator>
<dc:creator>Jochen Weile</dc:creator>
<dc:creator>Frederick Roth</dc:creator>
<dc:creator>Joe-Elie Salem</dc:creator>
<dc:creator>Nikki Earle</dc:creator>
<dc:creator>Rachael Stiles</dc:creator>
<dc:creator>Taylor Agee</dc:creator>
<dc:creator>Christopher N Johnson</dc:creator>
<dc:creator>Minoru Horie</dc:creator>
<dc:creator>Jonathan Skinner</dc:creator>
<dc:creator>Michael J Ackerman</dc:creator>
<dc:creator>Peter J Schwartz</dc:creator>
<dc:creator>Seiko Ohno</dc:creator>
<dc:creator>Jamie I Vandenberg</dc:creator>
<dc:creator>Brett M Kroncke</dc:creator>
<dc:date>2024-09-24</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Assays of Variant Effect and Automated Patch Clamping Improve &lt;em>;KCNH2&lt;/em>;-LQTS Variant Classification and Cardiac Event Risk Stratification</dc:title>
<dc:identifier>pmid:39315434</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069828</dc:identifier>
</item>
<item>
<title>Bone Morphogenetic Protein 9 Protects Against Myocardial Infarction by Improving Lymphatic Drainage Function and Triggering DECR1-Mediated Mitochondrial Bioenergetics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39315433/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240925021515&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These results suggest that BMP9 protects against MI by fine-tuning the multiorgan cross-talk among the liver, lymph, and the heart.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 24. doi: 10.1161/CIRCULATIONAHA.123.065935. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: BMP9 (bone morphogenetic protein 9) is a member of the TGF-β (transforming growth factor β) family of cytokines with pleiotropic effects on glucose metabolism, fibrosis, and lymphatic development. However, the role of BMP9 in myocardial infarction (MI) remains elusive.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The expressional profiles of BMP9 in cardiac tissues and plasma samples of subjects with MI were determined by immunoassay or immunoblot. The role of BMP9 in MI was determined by evaluating the impact of BMP9 deficiency and replenishment with adeno-associated virus-mediated BMP9 expression or recombinant human BMP9 protein in mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We show that circulating BMP9 and its cardiac levels are markedly increased in humans and mice with MI and are negatively associated with cardiac function. It is important to note that BMP9 deficiency exacerbates left ventricular dysfunction, increases infarct size, and augments cardiac fibrosis in mice with MI. In contrast, replenishment of BMP9 significantly attenuates these adverse effects. We further demonstrate that BMP9 improves lymphatic drainage function, thereby leading to a decrease of cardiac edema. In addition, BMP9 increases the expression of mitochondrial DECR1 (2,4-dienoyl-CoA reductase 1), a rate-limiting enzyme involved in β-oxidation, which, in turn, promotes cardiac mitochondrial bioenergetics and mitigates MI-induced cardiomyocyte injury. Moreover, DECR1 deficiency exacerbates MI-induced cardiac damage in mice, whereas this adverse effect is restored by the treatment of adeno-associated virus-mediated DECR1. Consistently, DECR1 deletion abrogates the beneficial effect of BMP9 against MI-induced cardiomyopathy and cardiac damage in mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These results suggest that BMP9 protects against MI by fine-tuning the multiorgan cross-talk among the liver, lymph, and the heart.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39315433/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240925021515&v=2.18.0.post9+e462414">39315433</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065935>10.1161/CIRCULATIONAHA.123.065935</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39315433</guid>
<pubDate>Tue, 24 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Zikun Duan</dc:creator>
<dc:creator>Zhouqing Huang</dc:creator>
<dc:creator>Wei Lei</dc:creator>
<dc:creator>Ke Zhang</dc:creator>
<dc:creator>Wei Xie</dc:creator>
<dc:creator>Hua Jin</dc:creator>
<dc:creator>Maolan Wu</dc:creator>
<dc:creator>Ningrui Wang</dc:creator>
<dc:creator>Xiaokun Li</dc:creator>
<dc:creator>Aimin Xu</dc:creator>
<dc:creator>Hao Zhou</dc:creator>
<dc:creator>Fan Wu</dc:creator>
<dc:creator>Yulin Li</dc:creator>
<dc:creator>Zhuofeng Lin</dc:creator>
<dc:date>2024-09-24</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Bone Morphogenetic Protein 9 Protects Against Myocardial Infarction by Improving Lymphatic Drainage Function and Triggering DECR1-Mediated Mitochondrial Bioenergetics</dc:title>
<dc:identifier>pmid:39315433</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065935</dc:identifier>
</item>
<item>
<title>NT-proBNP and Cardiac Troponin I, but Not Cardiac Troponin T, Are Associated With 7-Year Changes in Cardiac Structure and Function in Older Adults: The ARIC Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39315431/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240925021515&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Higher concentrations of NT-proBNP and hs-cTnI, but not hs-cTnT, were associated with greater declines in left ventricular function over ≈7 years in late life independently of traditional cardiovascular risk factors.AQ.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 24. doi: 10.1161/CIRCULATIONAHA.124.069735. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Higher circulating concentrations of NT-proBNP (N-terminal pro-B-type natriuretic peptide) and high-sensitivity cardiac troponin T (hs-cTnT) and I (hs-cTnI) are associated with left ventricular remodeling and with incident heart failure. The associations of these cardiac biomarkers with changes in cardiac structure and function over time are uncharacterized.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Among 2006 participants in the ARIC prospective cohort study (Atherosclerosis Risk in Communities) who were free of overt cardiovascular disease and underwent echocardiography at study visits 5 (2011- 2013) and 7 (2018-2019), we assessed the associations of NT-proBNP, hs-cTnT, and hs-cTnI concentrations at visit 5 with changes in left ventricular structure and function between visits 5 and 7 (≈7-year change) using multivariable linear regression with the biomarkers modeled as restricted cubic splines. Models were adjusted for age, sex, race, body mass index, smoking, diabetes, hypertension, and renal function at visit 5; blood pressure and heart rate at both visits; and the baseline value of the echocardiographic parameter of interest.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Mean±SD age was 74±4 years at visit 5; 61% were women; and 23% were Black adults. Median (25th-75th percentile) concentrations at visit 5 of NT-proBNP, hs-cTnT, and hs-cTnI were 87 ng/L (50-157 ng/L), 9 ng/L (6-12 ng/L), and 2.6 ng/L (1.9-3.9 ng/L). In adjusted models, elevated baseline concentrations of NT-proBNP and hs-cTnI were significantly associated with 7-year decline in left ventricular systolic function (ejection fraction, longitudinal and circumferential strain) and worsening diastolic indices. In contrast, elevated baseline concentrations of hs-cTnT were not significantly associated with 7-year changes in cardiac structure, systolic function, or diastolic function (all <i>P</i>>;0.05).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Higher concentrations of NT-proBNP and hs-cTnI, but not hs-cTnT, were associated with greater declines in left ventricular function over ≈7 years in late life independently of traditional cardiovascular risk factors.AQ.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39315431/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240925021515&v=2.18.0.post9+e462414">39315431</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069735>10.1161/CIRCULATIONAHA.124.069735</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39315431</guid>
<pubDate>Tue, 24 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Peder L Myhre</dc:creator>
<dc:creator>Brian Claggett</dc:creator>
<dc:creator>Christie M Ballantyne</dc:creator>
<dc:creator>Ron C Hoogeveen</dc:creator>
<dc:creator>Elizabeth Selvin</dc:creator>
<dc:creator>Kunihiro Matsushita</dc:creator>
<dc:creator>Dalane Kitzman</dc:creator>
<dc:creator>Suma Konety</dc:creator>
<dc:creator>Thomas Mosley</dc:creator>
<dc:creator>Amil M Shah</dc:creator>
<dc:date>2024-09-24</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>NT-proBNP and Cardiac Troponin I, but Not Cardiac Troponin T, Are Associated With 7-Year Changes in Cardiac Structure and Function in Older Adults: The ARIC Study</dc:title>
<dc:identifier>pmid:39315431</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069735</dc:identifier>
</item>
<item>
<title>Cryo-X-ray phase contrast imaging for 3D structural and molecular analysis of frozen biopsy samples</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39313557/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240925021515&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Sep 23. doi: 10.1038/s41569-024-01084-0. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39313557/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240925021515&v=2.18.0.post9+e462414">39313557</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01084-0>10.1038/s41569-024-01084-0</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39313557</guid>
<pubDate>Mon, 23 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Kan Yan Chloe Li</dc:creator>
<dc:creator>Anne Bonnin</dc:creator>
<dc:date>2024-09-23</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Cryo-X-ray phase contrast imaging for 3D structural and molecular analysis of frozen biopsy samples</dc:title>
<dc:identifier>pmid:39313557</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01084-0</dc:identifier>
</item>
<item>
<title>DNA Methylation Age Mediates Effect of Metabolic Profile on Cardiovascular and General Aging</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39308399/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240925021515&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These findings suggest that epigenomic mechanisms may play a role in the associations between circulating metabolites and the aging process. Different mechanisms underlie the first and second generations of DNA methylation age in cardiovascular and general aging.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Sep 23. doi: 10.1161/CIRCRESAHA.124.325066. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Alterations in lipid metabolism and DNA methylation are 2 hallmarks of aging. Connecting metabolomic, epigenomic, and aging outcomes help unravel the complex mechanisms underlying aging. We aimed to assess whether DNA methylation clocks mediate the association of circulating metabolites with incident atherosclerotic cardiovascular disease (ASCVD) and frailty.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The China Kadoorie Biobank is a prospective cohort study with a baseline survey from 2004 to 2008 and a follow-up period until December 31, 2018. We used the Infinium Methylation EPIC BeadChip to measure the methylation levels of 988 participants' baseline blood leukocyte DNA. Metabolite profiles, including lipoprotein particles, lipid constituents, and various circulating metabolites, were measured using quantitative nuclear magnetic resonance. The pace of DNA methylation age acceleration (AA) was calculated using 5 widely used epigenetic clocks (the first generation: Horvath, Hannum, and Li; the second generation: Grim and Pheno). Incident ASCVD was ascertained through linkage with local death and disease registries and national health insurance databases, supplemented by active follow-up. The frailty index was constructed using medical conditions, symptoms, signs, and physical measurements collected at baseline.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 508 incident cases of ASCVD were documented during a median follow-up of 9.5 years. The first generation of epigenetic clocks was associated with the risk of ASCVD (<i>P</i>&lt;0.05). For each SD increment in LiAA, HorvathAA, and HannumAA, the corresponding hazard ratios for ASCVD risk were 1.16 (1.05-1.28), 1.10 (1.00-1.22), and 1.17 (1.04-1.31), respectively. Only LiAA mediated the association of various metabolites (lipids, fatty acids, histidine, and inflammatory biomarkers) with ASCVD, with the mediating proportion reaching up to 15% for the diameter of low-density lipoprotein (<i>P</i>=1.2×10<sup>-</sup><sup>2</sup>). Regarding general aging, a 1-SD increase in GrimAA was associated with an average increase of 0.10 in the frailty index (<i>P</i>=2.0×10<sup>-</sup><sup>3</sup>), and a 33% and 63% increased risk of prefrailty and frailty at baseline (<i>P</i>=1.5×10<sup>-</sup><sup>2</sup> and 5.8×10<sup>-</sup><sup>2</sup>), respectively; this association was not observed with other clocks. GrimAA mediated the effect of various lipids, fatty acids, glucose, lactate, and inflammatory biomarkers on the frailty index, with the mediating proportion reaching up to 22% for triglycerides in very small-sized very low-density lipoprotein (<i>P</i>=6.0×10<sup>-</sup><sup>3</sup>).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings suggest that epigenomic mechanisms may play a role in the associations between circulating metabolites and the aging process. Different mechanisms underlie the first and second generations of DNA methylation age in cardiovascular and general aging.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39308399/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240925021515&v=2.18.0.post9+e462414">39308399</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325066>10.1161/CIRCRESAHA.124.325066</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39308399</guid>
<pubDate>Mon, 23 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Jiahui Si</dc:creator>
<dc:creator>Yu Ma</dc:creator>
<dc:creator>Canqing Yu</dc:creator>
<dc:creator>Dianjianyi Sun</dc:creator>
<dc:creator>Yuanjie Pang</dc:creator>
<dc:creator>Pei Pei</dc:creator>
<dc:creator>Ling Yang</dc:creator>
<dc:creator>Iona Y Millwood</dc:creator>
<dc:creator>Robin G Walters</dc:creator>
<dc:creator>Yiping Chen</dc:creator>
<dc:creator>Huaidong Du</dc:creator>
<dc:creator>Xiaoyan Zheng</dc:creator>
<dc:creator>Daniel Avery</dc:creator>
<dc:creator>Junshi Chen</dc:creator>
<dc:creator>Zhengming Chen</dc:creator>
<dc:creator>Liming Liang</dc:creator>
<dc:creator>Liming Li</dc:creator>
<dc:creator>Jun Lv</dc:creator>
<dc:creator>China Kadoorie Biobank Collaborative Group</dc:creator>
<dc:date>2024-09-23</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>DNA Methylation Age Mediates Effect of Metabolic Profile on Cardiovascular and General Aging</dc:title>
<dc:identifier>pmid:39308399</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325066</dc:identifier>
</item>
<item>
<title>Interatrial Shunt Treatment for Heart Failure: The Randomized RELIEVE-HF Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39308371/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240925021515&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Transcatheter interatrial shunt implantation was safe but did not improve outcomes in patients with HF. However, the results from a prespecified exploratory analysis in stratified randomized groups suggest that shunt implantation is beneficial in patients with reduced LVEF and harmful in patients with preserved LVEF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 23. doi: 10.1161/CIRCULATIONAHA.124.070870. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: An interatrial shunt may provide an autoregulatory mechanism to decrease left atrial pressure and improve heart failure (HF) symptoms and prognosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients with symptomatic HF with any left ventricular ejection fraction (LVEF) were randomized 1:1 to transcatheter shunt implantation versus a placebo procedure, stratified by reduced (≤40%) versus preserved (>;40%) LVEF. The primary safety outcome was a composite of device-related or procedure-related major adverse cardiovascular or neurological events at 30 days compared with a prespecified performance goal of 11%. The primary effectiveness outcome was the hierarchical composite ranking of all-cause death, cardiac transplantation or left ventricular assist device implantation, HF hospitalization, outpatient worsening HF events, and change in quality of life from baseline measured by the Kansas City Cardiomyopathy Questionnaire overall summary score through maximum 2-year follow-up, assessed when the last enrolled patient reached 1-year follow-up, expressed as the win ratio. Prespecified hypothesis-generating analyses were performed on patients with reduced and preserved LVEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Between October 24, 2018, and October 19, 2022, 508 patients were randomized at 94 sites in 11 countries to interatrial shunt treatment (n=250) or a placebo procedure (n=258). Median (25th and 75th percentiles) age was 73.0 years (66.0, 79.0), and 189 patients (37.2%) were women. Median LVEF was reduced (≤40%) in 206 patients (40.6%) and preserved (>;40%) in 302 patients (59.4%). No primary safety events occurred after shunt implantation (upper 97.5% confidence limit, 1.5%; <i>P</i>&lt;0.0001). There was no difference in the 2-year primary effectiveness outcome between the shunt and placebo procedure groups (win ratio, 0.86 [95% CI, 0.61-1.22]; <i>P</i>=0.20). However, patients with reduced LVEF had fewer adverse cardiovascular events with shunt treatment versus placebo (annualized rate 49.0% versus 88.6%; relative risk, 0.55 [95% CI, 0.42-0.73]; <i>P</i>&lt;0.0001), whereas patients with preserved LVEF had more cardiovascular events with shunt treatment (annualized rate 60.2% versus 35.9%; relative risk, 1.68 [95% CI, 1.29-2.19]; <i>P</i>=0.0001; <i>P</i><sub>interaction</sub>&lt;0.0001). There were no between-group differences in change in Kansas City Cardiomyopathy Questionnaire overall summary score during follow-up in all patients or in those with reduced or preserved LVEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Transcatheter interatrial shunt implantation was safe but did not improve outcomes in patients with HF. However, the results from a prespecified exploratory analysis in stratified randomized groups suggest that shunt implantation is beneficial in patients with reduced LVEF and harmful in patients with preserved LVEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03499236.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39308371/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240925021515&v=2.18.0.post9+e462414">39308371</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070870>10.1161/CIRCULATIONAHA.124.070870</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39308371</guid>
<pubDate>Mon, 23 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>JoAnn Lindenfeld</dc:creator>
<dc:creator>Josep Rodés-Cabau</dc:creator>
<dc:creator>Stefan D Anker</dc:creator>
<dc:creator>Michael R Zile</dc:creator>
<dc:creator>Saibal Kar</dc:creator>
<dc:creator>Richard Holcomb</dc:creator>
<dc:creator>Michael P Pfeiffer</dc:creator>
<dc:creator>Antoni Bayes-Genis</dc:creator>
<dc:creator>Jeroen J Bax</dc:creator>
<dc:creator>Alan J Bank</dc:creator>
<dc:creator>Maria Rosa Costanzo</dc:creator>
<dc:creator>Stefan Verheye</dc:creator>
<dc:creator>Ariel Roguin</dc:creator>
<dc:creator>Gerasimos Filippatos</dc:creator>
<dc:creator>Julio Núñez</dc:creator>
<dc:creator>Elizabeth C Lee</dc:creator>
<dc:creator>Michal Laufer-Perl</dc:creator>
<dc:creator>Gil Moravsky</dc:creator>
<dc:creator>Sheldon E Litwin</dc:creator>
<dc:creator>Edgard Prihadi</dc:creator>
<dc:creator>Hemal Gada</dc:creator>
<dc:creator>Eugene S Chung</dc:creator>
<dc:creator>Matthew J Price</dc:creator>
<dc:creator>Vinay Thohan</dc:creator>
<dc:creator>Dimitry Schewel</dc:creator>
<dc:creator>Sachin Kumar</dc:creator>
<dc:creator>Stephan Kische</dc:creator>
<dc:creator>Kevin S Shah</dc:creator>
<dc:creator>Daniel J Donovan</dc:creator>
<dc:creator>Yiran Zhang</dc:creator>
<dc:creator>Neal L Eigler</dc:creator>
<dc:creator>William T Abraham</dc:creator>
<dc:creator>RELIEVE-HF Investigators</dc:creator>
<dc:date>2024-09-23</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Interatrial Shunt Treatment for Heart Failure: The Randomized RELIEVE-HF Trial</dc:title>
<dc:identifier>pmid:39308371</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070870</dc:identifier>
</item>
<item>
<title>Profound cellular defects attribute to muscular pathogenesis in the rhesus monkey model of Duchenne muscular dystrophy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39305903/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240925021515&amp;v=2.18.0.post9+e462414
      <description>Duchenne muscular dystrophy (DMD) is a progressive muscle-wasting disease caused by mutations in the DMD gene. Muscle fibers rely on the coordination of multiple cell types for repair and regenerative capacity. To elucidate the cellular and molecular changes in these cell types under pathologic conditions, we generated a rhesus monkey model for DMD that displays progressive muscle deterioration and impaired motor function, mirroring human conditions. By leveraging these DMD monkeys, we analyzed...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 13:S0092-8674(24)00970-X. doi: 10.1016/j.cell.2024.08.041. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Duchenne muscular dystrophy (DMD) is a progressive muscle-wasting disease caused by mutations in the DMD gene. Muscle fibers rely on the coordination of multiple cell types for repair and regenerative capacity. To elucidate the cellular and molecular changes in these cell types under pathologic conditions, we generated a rhesus monkey model for DMD that displays progressive muscle deterioration and impaired motor function, mirroring human conditions. By leveraging these DMD monkeys, we analyzed freshly isolated muscle tissues using single-cell RNA sequencing (scRNA-seq). Our analysis revealed changes in immune cell landscape, a reversion of lineage progressing directions in fibrotic fibro-adipogenic progenitors (FAPs), and TGF-β resistance in FAPs and muscle stem cells (MuSCs). Furthermore, MuSCs displayed cell-intrinsic defects, leading to differentiation deficiencies. Our study provides important insights into the pathogenesis of DMD, offering a valuable model and dataset for further exploration of the underlying mechanisms, and serves as a suitable platform for developing and evaluating therapeutic interventions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39305903/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240925021515&v=2.18.0.post9+e462414">39305903</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.041>10.1016/j.cell.2024.08.041</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39305903</guid>
<pubDate>Sat, 21 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Shuaiwei Ren</dc:creator>
<dc:creator>Xin Fu</dc:creator>
<dc:creator>Wenting Guo</dc:creator>
<dc:creator>Raoxian Bai</dc:creator>
<dc:creator>Sheng Li</dc:creator>
<dc:creator>Ting Zhang</dc:creator>
<dc:creator>Jie Liu</dc:creator>
<dc:creator>Zhengbo Wang</dc:creator>
<dc:creator>Hui Zhao</dc:creator>
<dc:creator>Shengbao Suo</dc:creator>
<dc:creator>Weikang Zhang</dc:creator>
<dc:creator>Minzhi Jia</dc:creator>
<dc:creator>Weizhi Ji</dc:creator>
<dc:creator>Ping Hu</dc:creator>
<dc:creator>Yongchang Chen</dc:creator>
<dc:date>2024-09-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Profound cellular defects attribute to muscular pathogenesis in the rhesus monkey model of Duchenne muscular dystrophy</dc:title>
<dc:identifier>pmid:39305903</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.041</dc:identifier>
</item>
<item>
<title>m&lt;sup>;6&lt;/sup>;A-modified cenRNA stabilizes CENPA to ensure centromere integrity in cancer cells</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39305902/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240925021515&amp;v=2.18.0.post9+e462414
      <description>m⁶A modification is best known for its critical role in controlling multiple post-transcriptional processes of the mRNAs. Here, we discovered elevated levels of m⁶A modification on centromeric RNA (cenRNA) in cancerous cells compared with non-cancerous cells. We then identified CENPA, an H3 variant, as an m⁶A reader of cenRNA. CENPA is localized at centromeres and is essential in preserving centromere integrity and function during mitosis. The m⁶A-modified cenRNA stabilizes centromeric...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 18:S0092-8674(24)00969-3. doi: 10.1016/j.cell.2024.08.040. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">m<sup>6</sup>A modification is best known for its critical role in controlling multiple post-transcriptional processes of the mRNAs. Here, we discovered elevated levels of m<sup>6</sup>A modification on centromeric RNA (cenRNA) in cancerous cells compared with non-cancerous cells. We then identified CENPA, an H3 variant, as an m<sup>6</sup>A reader of cenRNA. CENPA is localized at centromeres and is essential in preserving centromere integrity and function during mitosis. The m<sup>6</sup>A-modified cenRNA stabilizes centromeric localization of CENPA in cancer cells during the S phase of the cell cycle. Mutations of CENPA at the Leu61 and the Arg63 or removal of cenRNA m<sup>6</sup>A modification lead to loss of centromere-bound CENPA during S phase. This in turn results in compromised centromere integrity and abnormal chromosome separation and hinders cancer cell proliferation and tumor growth. Our findings unveil an m<sup>6</sup>A reading mechanism by CENPA that epigenetically governs centromere integrity in cancer cells, providing potential targets for cancer therapy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39305902/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240925021515&v=2.18.0.post9+e462414">39305902</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.040>10.1016/j.cell.2024.08.040</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39305902</guid>
<pubDate>Sat, 21 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Zihong Kang</dc:creator>
<dc:creator>Ruimeng Li</dc:creator>
<dc:creator>Chang Liu</dc:creator>
<dc:creator>Xiaozhe Dong</dc:creator>
<dc:creator>Yuxuan Hu</dc:creator>
<dc:creator>Lei Xu</dc:creator>
<dc:creator>Xinyu Liu</dc:creator>
<dc:creator>Yunfan Xiang</dc:creator>
<dc:creator>Liming Gao</dc:creator>
<dc:creator>Wenzhe Si</dc:creator>
<dc:creator>Lei Wang</dc:creator>
<dc:creator>Qing Li</dc:creator>
<dc:creator>Liang Zhang</dc:creator>
<dc:creator>Huan Wang</dc:creator>
<dc:creator>Xuerui Yang</dc:creator>
<dc:creator>Jun Liu</dc:creator>
<dc:date>2024-09-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>m&lt;sup>;6&lt;/sup>;A-modified cenRNA stabilizes CENPA to ensure centromere integrity in cancer cells</dc:title>
<dc:identifier>pmid:39305902</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.040</dc:identifier>
</item>
<item>
<title>The molecular landscape of vascular cells in the human brain</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39304749/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240925021515&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Sep 20. doi: 10.1038/s41569-024-01079-x. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39304749/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240925021515&v=2.18.0.post9+e462414">39304749</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01079-x>10.1038/s41569-024-01079-x</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39304749</guid>
<pubDate>Fri, 20 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Elizabeth E Crouch</dc:creator>
<dc:date>2024-09-20</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>The molecular landscape of vascular cells in the human brain</dc:title>
<dc:identifier>pmid:39304749</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01079-x</dc:identifier>
</item>
<item>
<title>Lysosomes in the immunometabolic reprogramming of immune cells in atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39304748/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240925021515&amp;v=2.18.0.post9+e462414
      <description>Lysosomes have a central role in the disposal of extracellular and intracellular cargo and also function as metabolic sensors and signalling platforms in the immunometabolic reprogramming of macrophages and other immune cells in atherosclerosis. Lysosomes can rapidly sense the presence of nutrients within immune cells, thereby switching from catabolism of extracellular material to the recycling of intracellular cargo. Such a fine-tuned degradative response supports the generation of metabolic...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Sep 20. doi: 10.1038/s41569-024-01072-4. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Lysosomes have a central role in the disposal of extracellular and intracellular cargo and also function as metabolic sensors and signalling platforms in the immunometabolic reprogramming of macrophages and other immune cells in atherosclerosis. Lysosomes can rapidly sense the presence of nutrients within immune cells, thereby switching from catabolism of extracellular material to the recycling of intracellular cargo. Such a fine-tuned degradative response supports the generation of metabolic building blocks through effectors such as mTORC1 or TFEB. By coupling nutrients to downstream signalling and metabolism, lysosomes serve as a crucial hub for cellular function in innate and adaptive immune cells. Lysosomal dysfunction is now recognized to be a hallmark of atherogenesis. Perturbations in nutrient-sensing and signalling have profound effects on the capacity of immune cells to handle cholesterol, perform phagocytosis and efferocytosis, and limit the activation of the inflammasome and other inflammatory pathways. Strategies to improve lysosomal function hold promise as novel modulators of the immunoinflammatory response associated with atherosclerosis. In this Review, we describe the crosstalk between lysosomal biology and immune cell function and polarization, with a particular focus on cellular immunometabolic reprogramming in the context of atherosclerosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39304748/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240925021515&v=2.18.0.post9+e462414">39304748</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01072-4>10.1038/s41569-024-01072-4</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39304748</guid>
<pubDate>Fri, 20 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Fabrizia Bonacina</dc:creator>
<dc:creator>Xiangyu Zhang</dc:creator>
<dc:creator>Nicolas Manel</dc:creator>
<dc:creator>Laurent Yvan-Charvet</dc:creator>
<dc:creator>Babak Razani</dc:creator>
<dc:creator>Giuseppe D Norata</dc:creator>
<dc:date>2024-09-20</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Lysosomes in the immunometabolic reprogramming of immune cells in atherosclerosis</dc:title>
<dc:identifier>pmid:39304748</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01072-4</dc:identifier>
</item>
<item>
<title>Nothing about us without us: Sharing results with communities that provide genomic data</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39303717/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240925021515&amp;v=2.18.0.post9+e462414
      <description>Sharing genetic and other study results with the communities who participate in research falls under benefit-sharing and capacity-building initiatives that underpin a more equitable biomedical research relationship. Yet, which results to return and how remain fundamental challenges that persist in the absence of practical guidance and institutional policies. Here, we discuss how the return of results can be implemented across different geographies, study designs, and project budgets.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 4:S0092-8674(24)00916-4. doi: 10.1016/j.cell.2024.08.023. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Sharing genetic and other study results with the communities who participate in research falls under benefit-sharing and capacity-building initiatives that underpin a more equitable biomedical research relationship. Yet, which results to return and how remain fundamental challenges that persist in the absence of practical guidance and institutional policies. Here, we discuss how the return of results can be implemented across different geographies, study designs, and project budgets.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39303717/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240925021515&v=2.18.0.post9+e462414">39303717</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.023>10.1016/j.cell.2024.08.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39303717</guid>
<pubDate>Fri, 20 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Sarah LeBaron von Baeyer</dc:creator>
<dc:creator>Rebecca M Crocker</dc:creator>
<dc:creator>Rindra Rakotoarivony</dc:creator>
<dc:creator>Jean Freddy Ranaivoarisoa</dc:creator>
<dc:creator>Germain Jules Spiral</dc:creator>
<dc:creator>Tristan Pascart</dc:creator>
<dc:creator>Vehia Wheeler</dc:creator>
<dc:creator>Tehani Mairai</dc:creator>
<dc:creator>Noomi O Gregersen</dc:creator>
<dc:creator>Stephane E Castel</dc:creator>
<dc:creator>Laura M Yerges-Armstrong</dc:creator>
<dc:creator>Keolu Fox</dc:creator>
<dc:creator>Kaja A Wasik</dc:creator>
<dc:date>2024-09-20</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Nothing about us without us: Sharing results with communities that provide genomic data</dc:title>
<dc:identifier>pmid:39303717</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.023</dc:identifier>
</item>
<item>
<title>A transmitochondrial sodium gradient controls membrane potential in mammalian mitochondria</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39303716/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240925021515&amp;v=2.18.0.post9+e462414
      <description>Eukaryotic cell function and survival rely on the use of a mitochondrial H^(+) electrochemical gradient (Δp), which is composed of an inner mitochondrial membrane (IMM) potential (ΔΨmt) and a pH gradient (ΔpH). So far, ΔΨmt has been assumed to be composed exclusively of H^(+). Here, using a rainbow of mitochondrial and nuclear genetic models, we have discovered that a Na^(+) gradient equates with the H^(+) gradient and controls half of ΔΨmt in coupled-respiring mammalian mitochondria. This...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 17:S0092-8674(24)00974-7. doi: 10.1016/j.cell.2024.08.045. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Eukaryotic cell function and survival rely on the use of a mitochondrial H<sup>+</sup> electrochemical gradient (Δp), which is composed of an inner mitochondrial membrane (IMM) potential (ΔΨmt) and a pH gradient (ΔpH). So far, ΔΨmt has been assumed to be composed exclusively of H<sup>+</sup>. Here, using a rainbow of mitochondrial and nuclear genetic models, we have discovered that a Na<sup>+</sup> gradient equates with the H<sup>+</sup> gradient and controls half of ΔΨmt in coupled-respiring mammalian mitochondria. This parallelism is controlled by the activity of the long-sought Na<sup>+</sup>-specific Na<sup>+</sup>/H<sup>+</sup> exchanger (mNHE), which we have identified as the P-module of complex I (CI). Deregulation of this mNHE function, without affecting the canonical enzymatic activity or the assembly of CI, occurs in Leber's hereditary optic neuropathy (LHON), which has profound consequences in ΔΨmt and mitochondrial Ca<sup>2+</sup> homeostasis and explains the previously unknown molecular pathogenesis of this neurodegenerative disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39303716/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240925021515&v=2.18.0.post9+e462414">39303716</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.045>10.1016/j.cell.2024.08.045</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39303716</guid>
<pubDate>Fri, 20 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Pablo Hernansanz-Agustín</dc:creator>
<dc:creator>Carmen Morales-Vidal</dc:creator>
<dc:creator>Enrique Calvo</dc:creator>
<dc:creator>Paolo Natale</dc:creator>
<dc:creator>Yolanda Martí-Mateos</dc:creator>
<dc:creator>Sara Natalia Jaroszewicz</dc:creator>
<dc:creator>José Luis Cabrera-Alarcón</dc:creator>
<dc:creator>Rebeca Acín-Pérez</dc:creator>
<dc:creator>Iván López-Montero</dc:creator>
<dc:creator>Jesús Vázquez</dc:creator>
<dc:creator>José Antonio Enríquez</dc:creator>
<dc:date>2024-09-20</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A transmitochondrial sodium gradient controls membrane potential in mammalian mitochondria</dc:title>
<dc:identifier>pmid:39303716</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.045</dc:identifier>
</item>





























</channel>
</rss>